Subscribe to RSS
DOI: 10.1055/s-0043-1778109
Anaplastic Thyroid Carcinoma versus Metastatic SCC: A Diagnostic Dilemma in a Rare Presentation of Post-Radiation Thyroid Swelling
Funding None.Abstract
A 71-year-old male with type 2 diabetes and hypertension was diagnosed with carcinoma of the pyriform fossa in 2019. The biopsy was reported as a moderately differentiated squamous cell carcinoma, and positron emission tomography-computed tomography (PET-CT) scan showed an fluorodeoxyglucose (FDG)-avid lesion in the pyriform fossa and the aryepiglottic fold with few nodes in level II and level III. The paitent was treated with radical chemoradiotherapy. A follow-up PET-CT scan done in 2022 revealed an FDG-avid soft tissue thickening in the left palatine tonsillar region and an uptake in the thyroid that was reported as not significant. A punch biopsy from the tonsillar fossa lesion revealed squamous cell carcinoma. The lesion was treated as a second primary and treated with radiotherapy with curative intent. The patient was complaining of dysphagia, difficulty in breathing, and weight loss around 6 months after treatment that were addressed medically. There was a significant reduction in size and FDG activity of the ill-defined thickening in the left tonsillar region which was seen in the response-assessment PET done 6 months after RT. A heterogeneously enhancing nodules were seen in both lobes of the thyroid in which the largest one measured 3.5 × 3.1 cm seen in the right lobe. The patient underwent a biopsy from the thyroid that revealed a benign thyroid gland infiltrated by clusters and nests of poorly differentiated malignant cells. The histomorphology was suggestive of a poorly differentiated carcinoma, likely anaplastic carcinoma thyroid, or metastasis of the squamous cell carcinoma. Curative treatment was ruled out in this case due to his comorbidities, pulmonary symptoms, and radiation delivered to the neck.
Keywords
anaplastic thyroid carcinoma - medical oncology - metastatic squamous cell carcinoma - nuclear medicine - pathology - radiation oncologyDeclaration of Patient Consent
The authors certify that they have obtained all appropriate patient consent forms.
The manuscript has been read and approved by all the authors, that the requirements for authorship have been met, and that each author believes that the manuscript represents honest work, if that information is not provided in another form.
Criteria for inclusion of authors—Case management, data collection, proofreading the content.
Data Sharing Statement
All data generated and analyzed during this study are included in this published article. Research data are stored in an institutional repository and will be shared upon request to the corresponding author.
Publication History
Article published online:
21 March 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Limaiem F, Kashyap S, Naing PT, Giwa AO. Anaplastic Thyroid Cancer. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023
- 2 Gétaz EP, Shimaoka K, Rao U. Anaplastic carcinoma of the thyroid following external irradiation. Cancer 1979; 43 (06) 2248-2253
- 3 Xu B, Fuchs T, Dogan S. et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 2020; 30 (10) 1505-1517
- 4 Basheeth N, Patil N. Biomarkers in head and neck cancer an update. Indian J Otolaryngol Head Neck Surg 2019; 71 (Suppl. 01) 1002-1011
- 5 Park JW, Choi SH, Yoon HI. et al. Treatment outcomes of radiotherapy for anaplastic thyroid cancer. Radiat Oncol J 2018; 36 (02) 103-113
- 6 Yeh SA. Radiotherapy for head and neck cancer. Semin Plast Surg 2010; 24 (02) 127-136
- 7 Xu B, Zhang L, Setoodeh R. et al. Prolonged survival of anaplastic thyroid carcinoma is associated with resectability, low tumor-infiltrating neutrophils/myeloid-derived suppressor cells, and low peripheral neutrophil-to-lymphocyte ratio. Endocrine 2022; 76 (03) 612-619
- 8 Girolami I, Pantanowitz L, Mete O. et al. Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma. Endocr Pathol 2020; 31 (03) 291-300
- 9 Gauthaman A, Moorthy A. High incidence of BRAF V600 mutation in Indian patients with head and neck cancer. Front Biosci (Elite Ed) 2018; 10 (03) 520-527
- 10 Chang CF, Yang MH, Lee JH. et al. The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan. Am J Cancer Res 2022; 12 (11) 5342-5350
- 11 Uppaluri R, Winkler AE, Lin T. et al. Biomarker and tumor responses of oral cavity squamous cell carcinoma to trametinib: a phase ii neoadjuvant window-of-opportunity clinical trial. Clin Cancer Res 2017; 23 (09) 2186-2194
- 12 Goyal A, Gupta R, Mehmood S, Deo S, Mishra S, Bhatnagar S. Palliative and end of life care issues of carcinoma thyroid patient. Indian J Palliat Care 2012; 18 (02) 134-137